Equillium
EQ | NASDAQ
$1.15
-$0.14 (-10.85%)
At close: Nov 16, 2026, 4:00 PM ET
$1.15
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
-10.85%
(1D)No price chart data available for 1D timeframe.
Rating
25
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #929/1021 (Top 91%)
Key Statistics
Market Data
Market Cap $128.71M
1D Range
1.14 1.28
52W Range
0.85 3.20
Valuation (TTM)
PE -6.39
PB 2.44
EV/EBITDA -4.08
Valuation (NTM)
Forward PE N/A
Forward PEG 0.14
Price Target $5.50
Cash Flow
FCF Yield -12.0%
SBC Adj. FCF Yield -15.2%
SBC Impact -25.9%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -136.9% |
-20.6%
Dil EPS 3Y | 5Y -7.6% |
62.4%
FCF 3Y | 5Y 15.1% |
14.8%
Returns
ROA -32.9%
ROE -37.3%
ROIC -37.0%
Financial Health
Net Cash
$53.32M
Current Ratio 19.49
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorde...
Sector Healthcare
Industry Biotechnology
Employees 14
IPO Date Oct 12, 2018
Website equilliumbio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$5.50
Upside
+378.26%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove EQ